Literature DB >> 32688387

Therapy-induced mutagenesis in relapsed ALL is supported by mutational signature analysis.

Samuel W Brady1, Xiaotu Ma1, Bin-Bing S Zhou2,3, Ching-Hon Pui4, Jun J Yang5, Jinghui Zhang1.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32688387      PMCID: PMC7862874          DOI: 10.1182/blood.2020008107

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  6 in total

1.  Preexisting or therapy-induced mutations in relapsed acute lymphoblastic leukemia?

Authors:  Paul S Gaynon; Etan Orgel; Lingyun Ji
Journal:  Blood       Date:  2020-11-05       Impact factor: 22.113

2.  Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL.

Authors:  Benshang Li; Hui Li; Yun Bai; Renate Kirschner-Schwabe; Jun J Yang; Yao Chen; Gang Lu; Gannie Tzoneva; Xiaotu Ma; Tongmin Wu; Wenjing Li; Haisong Lu; Lixia Ding; Huanhuan Liang; Xiaohang Huang; Minjun Yang; Lei Jin; Hui Kang; Shuting Chen; Alicia Du; Shuhong Shen; Jianping Ding; Hongzhuan Chen; Jing Chen; Arend von Stackelberg; Longjun Gu; Jinghui Zhang; Adolfo Ferrando; Jingyan Tang; Shengyue Wang; Bin-Bing S Zhou
Journal:  Nat Med       Date:  2015-05-11       Impact factor: 53.440

3.  Relapse-Fated Latent Diagnosis Subclones in Acute B Lineage Leukemia Are Drug Tolerant and Possess Distinct Metabolic Programs.

Authors:  Laura García-Prat; Robert J Vanner; Jeffrey Wintersinger; Esmé Waanders; Stephanie M Dobson; Zhaohui Gu; Jessica McLeod; Olga I Gan; Ildiko Grandal; Debbie Payne-Turner; Michael N Edmonson; Xiaotu Ma; Yiping Fan; Veronique Voisin; Michelle Chan-Seng-Yue; Stephanie Z Xie; Mohsen Hosseini; Sagi Abelson; Pankaj Gupta; Michael Rusch; Ying Shao; Scott R Olsen; Geoffrey Neale; Steven M Chan; Gary Bader; John Easton; Cynthia J Guidos; Jayne S Danska; Jinghui Zhang; Mark D Minden; Quaid Morris; Charles G Mullighan; John E Dick
Journal:  Cancer Discov       Date:  2020-02-21       Impact factor: 39.397

4.  Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia.

Authors:  Benshang Li; Samuel W Brady; Xiaotu Ma; Shuhong Shen; Yingchi Zhang; Yongjin Li; Karol Szlachta; Li Dong; Yu Liu; Fan Yang; Ningling Wang; Diane A Flasch; Matthew A Myers; Heather L Mulder; Lixia Ding; Yanling Liu; Liqing Tian; Kohei Hagiwara; Ke Xu; Xin Zhou; Edgar Sioson; Tianyi Wang; Liu Yang; Jie Zhao; Hui Zhang; Ying Shao; Hongye Sun; Lele Sun; Jiaoyang Cai; Hui-Ying Sun; Ting-Nien Lin; Lijuan Du; Hui Li; Michael Rusch; Michael N Edmonson; John Easton; Xiaofan Zhu; Jingliao Zhang; Cheng Cheng; Benjamin J Raphael; Jingyan Tang; James R Downing; Ludmil B Alexandrov; Bin-Bing S Zhou; Ching-Hon Pui; Jun J Yang; Jinghui Zhang
Journal:  Blood       Date:  2020-01-02       Impact factor: 25.476

5.  The topography of mutational processes in breast cancer genomes.

Authors:  Sandro Morganella; Ludmil B Alexandrov; Dominik Glodzik; Xueqing Zou; Helen Davies; Johan Staaf; Anieta M Sieuwerts; Arie B Brinkman; Sancha Martin; Manasa Ramakrishna; Adam Butler; Hyung-Yong Kim; Åke Borg; Christos Sotiriou; P Andrew Futreal; Peter J Campbell; Paul N Span; Steven Van Laere; Sunil R Lakhani; Jorunn E Eyfjord; Alastair M Thompson; Hendrik G Stunnenberg; Marc J van de Vijver; John W M Martens; Anne-Lise Børresen-Dale; Andrea L Richardson; Gu Kong; Gilles Thomas; Julian Sale; Cristina Rada; Michael R Stratton; Ewan Birney; Serena Nik-Zainal
Journal:  Nat Commun       Date:  2016-05-02       Impact factor: 14.919

6.  Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia.

Authors:  Gannie Tzoneva; Chelsea L Dieck; Koichi Oshima; Alberto Ambesi-Impiombato; Marta Sánchez-Martín; Chioma J Madubata; Hossein Khiabanian; Jiangyan Yu; Esme Waanders; Ilaria Iacobucci; Maria Luisa Sulis; Motohiro Kato; Katsuyoshi Koh; Maddalena Paganin; Giuseppe Basso; Julie M Gastier-Foster; Mignon L Loh; Renate Kirschner-Schwabe; Charles G Mullighan; Raul Rabadan; Adolfo A Ferrando
Journal:  Nature       Date:  2018-01-17       Impact factor: 49.962

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.